Drug interactions
Glecaprevir / pibrentasvir + Linagliptin-metformin
Severity: Minor
Glecaprevir / pibrentasvir and Linagliptin-metformin: minor interaction.
Last updated
For healthcare professionals — reference only. This page is a brief summary, not medical advice and not a substitute for official labeling or clinical judgement. Always verify before prescribing or dispensing.
Summary
Glecaprevir and pibrentasvir inhibit P-glycoprotein and may modestly raise linagliptin concentrations. Linagliptin has a wide safety margin, so the clinical effect is expected to be small.
What this interaction means in plain words
Glecaprevir / pibrentasvir and Linagliptin-metformin have a small, usually unimportant interaction. Most people can take both; the pharmacist may still mention it so that any unexpected effect is recognised.
Why it happens
Inhibition of intestinal P-glycoprotein efflux increases linagliptin absorption and exposure.
What to do
No dose change is usually needed; monitor glucose control as routine when starting or stopping hepatitis C therapy, since improved liver function and viral clearance can also alter glycemia.
What to ask your pharmacist
- Is there anything I should notice while taking both?
- Do I need to tell my doctor at the next visit?
Pro+ members
Unlock the full page
Create an account and start a Pro+ trial to unlock the full management advice for Glecaprevir / pibrentasvir and Linagliptin-metformin, the additional notes, the evidence detail and the whole-prescription interaction checker.
- Full clinical management advice
- Additional notes
- Evidence detail
- Interaction checker for a whole prescription
Try Pro+ free for 14 days on the web. No card needed.
Other interactions of Linagliptin-metformin
Frequently asked questions
Can I take Glecaprevir / pibrentasvir with Linagliptin-metformin?
MediHelp rates the interaction as minor. Glecaprevir / pibrentasvir and Linagliptin-metformin have a small, usually unimportant interaction. Most people can take both; the pharmacist may still mention it so that any unexpected effect is recognised. Glecaprevir and pibrentasvir inhibit P-glycoprotein and may modestly raise linagliptin concentrations. Linagliptin has a wide safety margin, so the clinical effect is expected to be small.
How serious is the interaction between Glecaprevir / pibrentasvir and Linagliptin-metformin?
MediHelp rates it minor, on a four-level scale (minor, moderate, major, contraindicated) based on published labels and references. What to do, in brief: No dose change is usually needed; monitor glucose control as routine when starting or stopping hepatitis C therapy, since improved liver function and viral clearance can also alter glycemia.
What other medicines interact with Linagliptin-metformin?
MediHelp also lists interactions of Linagliptin-metformin with, for example, Apalutamide, Carbamazepine, Contrast media. The full list is on the Linagliptin-metformin page.
Full monographs, dosing and an interaction checker in the MediHelp app
Open the complete reference, check multi-drug interactions and use dosing tools in the MediHelp app.
